Phagenesis will become Chad Hoskins’ Chief Executive Officer after a Series D financing run of around 42 million. USD page 1

• Erfahrene Führungspersönlichkeit brings strong Erfolgsbilanz in der ommerziellen Expansion in the US of
• The company concentrates itself, the market operation of Phagenyx to support, a more patients in the US and Europe are dealing with their problems
• Phagenyx is the first therapy in the art, the neurostimulation of the recovery lung of the disease control in patients with schweren-schluckstörungen (dysphagia) einsetzt

MANCHESTER, England, 5. September 2024 /PRNewswire/ — The British pioneering company phagenesis, the new neurostimulation system with the treatment of the shock effect, will promote the Ernennung von Chad Hoskins to the Chief Executive Officer (CEO) known. The hereditary manager brings years of expertise in innovative MedTech therapy, financing of healthcare woes US en der Erreichung strategic Ziele mit.